Last reviewed 2026-04-19 · How we verify

MEOBENTINE

Phase 2 active Small molecule

MEOBENTINE is a drug. It is currently in Phase 2 development.

MEOBENTINE works by interacting with specific biological pathways to produce its therapeutic effect.

MEOBENTINE is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a small molecule, it is likely to work by interacting with specific biological pathways, but the exact mechanism is unknown. Further research is needed to determine its efficacy and safety profile. Its development and ownership history are also unclear.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MEOBENTINE
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like a orchestra, and MEOBENTINE is like a conductor that helps the cells work together in harmony. By interacting with specific pathways, MEOBENTINE can help restore balance and function to the cells, leading to its therapeutic effect. However, the exact details of how it does this are still unknown.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MEOBENTINE CI brief — competitive landscape report
MEOBENTINE updates RSS · CI watch RSS

Frequently asked questions about MEOBENTINE

What is MEOBENTINE?

MEOBENTINE is a Small molecule drug.

How does MEOBENTINE work?

MEOBENTINE works by interacting with specific biological pathways to produce its therapeutic effect.

What development phase is MEOBENTINE in?

MEOBENTINE is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing